Testing effectiveness (Phase 2)Study completedNCT01253447
What this trial is testing
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)+12 more
National Cancer Institute (NCI) 19